Pipeline

PipelineTargetIndicationPhase 1APhase 2B
TR009VEGF/DLL4
(Dual Angiogenic/DLL4 Notch1 Blocker)
Gastric, Colorectal, Ovarian, Pancreatic, NSCLC, GBM, TNBC, HCCCompletedDose Expansion & Combination
TRIA001*4-1BB/BCMA
(Immunotherapy)
Multiple Myeloma
First in Class
IND
Q1, 2021E

TRIA0024-1BB/+IO CheckPoint
(Immunotherapy)
Solid Tumors
First in Class
IND
Q4, 2021E

*ABL Bio retains S Korea rights to all compounds; TRIGR holds GLOBAL rights to all compounds, *Excluding Japan & certain Asia Pacific territories.

TR009 – Dual Angiogenic Bispecific

TR009 (ABL001) is a next generation anti-angiogenic bispecific antibody that specifically inhibits the VEGF and DLL4/Notch1 pathways. Its mechanism of action targets  both tumor angiogenesis and cancer stem cells (CSCs). Anti-angiogenic therapy is a cornerstone in cancer care, with sales of Avastin® (Roche) and Cymraza® (Eli Lilly) etc. surpassing $20 billion in 2018. Although this class of drugs has proven survival benefits and a mainstay therapy in various tumors including colorectal, lung, ovarian and gastric, resistance to current VEGF drugs creates the need for alternative anti-angiogenic regimens. Simultaneously blocking both VEFG and DLL4 is the next frontier of angiogenic therapy as this mechanism has been shown to overcome multi-VEGF resistance. 

In its Phase 1A dose escalation study, TR009  as a single agent demonstrated a Clinical Benefit Rate (CBR) of 71% in heavily pre-treated patients that had failed all available chemo and biological therapy (including VEGF, VEGF-R2, PD-1/PD-L1, EGFR). 

Gastric cancer patients had a 88% CBR (SD + PR) with mean treatment duration of around 5months; while colorectal Cancer had a 66% CBR (SD) with mean treatment duration of around 7 months. TR009 is currently being tested in a Phase 1B monotherapy expansion study and a Phase 1B combination study with irinotecan and paclitaxel (PD-1/PD-L1 pending) is expected to be initiated in Q2’2020.

Immune Cell Engaging Bispecifics

4-1BB (CD137) is an inducible co-stimulatory  molecule on CD4+ T cells, CD8+ T cells, regulatory T cells (Treg), NK Cells and dentritic cells. TRIGR’s  Immune Cell Engaging bispecifics (TRIA001 and TRIA002) leverage on a proprietary 4-1BB clone which binds to a unique epitope (CRD4) that does not compete with 4-1BBL. TRIGR’s anti-41BB are engineered to activate upon cross-linking with target tumor antigens (TAA) at tumor micro-environment. TRIA001 is a proprietary, first in class 4-1BB/BCMA bispecific antibody for multiple myeloma. TRIA002 is a proprietary, first in class 4-1BB/undisclosed checkpoint bispecific antibody for solid tumors.